Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diagnostic Performance of an Automated Breast Ultrasound System (ABUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02661204
Recruitment Status : Recruiting
First Posted : January 22, 2016
Last Update Posted : October 12, 2018
Sponsor:
Information provided by (Responsible Party):
University of Zurich

Brief Summary:

The purpose of this study is to evaluate the diagnostic performance of a new ABUS system among 4 different population:

Population A: women undergoing screening for familial or genetic predisposition for breast cancer.

Population B: women with newly diagnosed breast cancer. ABUS performance will be compared to breast MRI in the pre-operative assessment of breast cancer extent.

Population C: women with BI-RADS 3 or 4 lesions in a routine breast imaging examination. ABUS will be evaluate as a problem-solving tool.

Population D: women undergoing breast MRI for the assessment of breast implants integrity. ABUS performance will be compared to breast MRI.


Condition or disease Intervention/treatment
Breast Cancer Implants Device: Automated breast ultrasound examination (ABUS)

Detailed Description:

Population A: women in the age range of 20 to 40 years, with a strong family history of breast cancer or a predisposing gene mutation such as BRCA1 or BRCA2. A total of 100 patients should be enrolled.

Population B: women with new breast cancer diagnosis undergoing pre-operative local cancer staging.A total of 50 patients will be enrolled.

Population C: women with lesions classified BI-RADS 3 or 4 in a routine breast imaging examination. A total of 50 patients will be enrolled.

Population D: women undergoing breast-MRI for the evaluation of breast implants integrity. A total of 50 patients will be enrolled.

The expected duration of subject participation is 5 years for population A: every year the patients will undergo ABUS examination and the results will be compared with HHUS examination.

In population B, C and D only one examination will be performed and the data obtained with ABUS will be compared with HH-US and breast MRI data.

Images will be evaluated by a radiologist with breast imaging experience and ABUS findings will be compared with findings from HHUS and MR imaging.

Afterwards, two or three readers (radiologists with different levels of experience in breast imaging) blinded to clinical, HH-US and MRI data, will evaluate the interobserver agreement ABUS images will be evaluated by Methods of minimising bias Population A - During the recruitment, family history of breast cancer will be in-depth analysed in order to avoid the bias related to different levels of risk for breast cancer. In order to reduce the loss of patients to follow-up, women will be invited every year to undergo HHUS and ABUS examination at our department.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 250 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diagnostic Performance of an Automated Breast Ultrasound System (ABUS): a Single Centre Study
Study Start Date : January 2016
Estimated Primary Completion Date : January 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound

Group/Cohort Intervention/treatment
Population A
Consecutive women in the age range 20 to 40 years, with a strong family history of breast cancer or a predisposing gene mutation such as BRCA1 or BRCA2, referring to our department for breast evaluation with ultrasound, will be invited to participate to the study. During the interview, before imaging examination, women will be questioned about family history as well as other relevant personal information (e.g. previous surgery or biopsy for benign breast disease).
Device: Automated breast ultrasound examination (ABUS)
Automated breast ultrasound examination

Population B
Consecutive women with a new breast cancer diagnosis and undergoing pre-operative MRI examination for local staging will be invited to participate to the study. ABUS will be performed within two weeks before the scheduled surgery.
Device: Automated breast ultrasound examination (ABUS)
Automated breast ultrasound examination

Population C
Consecutive women with BI-RADS 3 and 4 lesions detected in a routine breast imaging examination will be invited to participate to the study. ABUS will be performed just after the routine HH-US examination.
Device: Automated breast ultrasound examination (ABUS)
Automated breast ultrasound examination

Population D
Consecutive women undergoing breast MRI examination for the evaluation of breast implants integrity will be invited to participate to the study. ABUS will be performed just after the breast MRI.
Device: Automated breast ultrasound examination (ABUS)
Automated breast ultrasound examination




Primary Outcome Measures :
  1. Population A: comparison between ABUS and HHUS with respect to the number of lesions detected with the two devices and their characterization according to the BI-RADS lexicon [ Time Frame: 5 years ]
  2. Population B:comparison between ABUS and breast MRI with respect to known malignant lesion/s size assessment and number of additional lesions detected and not previously evident with mammography and HHUS [ Time Frame: 5 years ]
    sensitivity and specificity of a new ABUS system in the assessment of breast cancer extent. Breast MRI will be used as standard of reference

  3. Population C: number of patients with diagnosis of BI-RADS 3 and 4 breast lesions with ABUS compared to histological results or follow-up [ Time Frame: 5 years ]
    sensitivity and specificity of a new ABUS system in the assessment of BI-RADS 3 and 4 lesions. Follow-up and histological results of the biopsy or surgery will be used as standard of reference

  4. Population D: number of participants with suspected rupture of breast implants diagnosed with ABUS compared to breast MRI diagnosis [ Time Frame: 5 years ]
    sensitivity and specificity of a new ABUS system in the assessment of breast implants integrity. Breast MRI will be used as standard of reference



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Population A: women in the age range of 20 to 40 years, with a strong family history of breast cancer or a predisposing gene mutation such as BRCA1 or BRCA2. A total of 100 patients should be enrolled.

Population B: women with new breast cancer diagnosis undergoing pre-operative local cancer staging.A total of 50 patients will be enrolled.

Population C: women with lesions classified BI-RADS 3 or 4 in a routine breast imaging examination. A total of 50 patients will be enrolled.

Population D: women undergoing breast-MRI for the evaluation of breast implants integrity. A total of 50 patients will be enrolled.

Criteria

Inclusion Criteria:

  1. Population A - Inclusion criteria:

    • Age between 20 and 40 years
    • family history of breast cancer or a proved predisposing gene mutation such as BRCA1 or BRCA2
  2. Population B - Inclusion criteria

    • Age ≥ 18 years
    • Newly diagnosed breast cancer with no previous history of breast cancer
    • Availability of pre-operative breast MRI performed for local staging within 4 weeks before the surgery
    • Breast surgery performed at the UniversitätsSpital Zürich
  3. Population C - Inclusion criteria

    • Age ≥ 18 years
    • Newly detected BI-RADS 3 or 4 lesion
    • Availability of follow-up examination or histological results of biopsy and surgery
  4. Population D - Inclusion criteria

    • Age ≥ 18 years
    • Availability of breast MRI performed for evaluating breast implants integrity

Exclusion Criteria:

1) Population A - Exclusion criteria:

  • Personal history of breast or ovarian cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02661204


Contacts
Layout table for location contacts
Contact: Andreas Boss, MD andreas.boss@usz.ch

Locations
Layout table for location information
Switzerland
University Hospital Zurich, Institute of Diagnostic and Interventional Radiology, University Hospital Zurich Recruiting
Zurich, Switzerland, 8091
Contact: Andreas Boss, MD    +41442553677    andreas.boss@usz.ch   
Sponsors and Collaborators
University of Zurich
Investigators
Layout table for investigator information
Principal Investigator: Andreas Boss, MD University Hospital Zurich, Institute of Diagnostic and Interventional Radiology, University Hospital Zurich

Layout table for additonal information
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT02661204     History of Changes
Other Study ID Numbers: BASEC 2015-00011
First Posted: January 22, 2016    Key Record Dates
Last Update Posted: October 12, 2018
Last Verified: October 2018